Member of the Board of Trustees Prof. Dr. Thorsten Schlomm Prof. Dr. Thorsten Schlomm is an internationally renowned expert in urological oncology with a particular focus on the diagnosis and treatment of prostate cancer. Since 2018, he has been Director of the Urology Clinic at Charité – Universitätsmedizin Berlin. Previously, as senior physician and scientific director, he played a key role in shaping the work at the Martini Clinic and the University Medical Center Hamburg-Eppendorf. In his clinical work, Prof. Schlomm combines state-of-the-art oncological therapy methods with translational research in order to directly translate new scientific findings into improved patient care. His research focuses on the genetic and molecular analysis of tumors and the development of personalized therapy approaches in the field of precision oncology. As an active partner in international research collaborations, he is committed to the integration of genomic medicine, digital medicine, and clinical oncology. He is equally passionate about the responsible use of medical data and the promotion of innovative, patient-centered care models for the sustainable improvement of prevention, diagnostics, and therapy. Member of the Board of Trustees Jan Franz Jan Franz is a urologist and oncologist in private practice in Tostedt, Lower Saxony. Since setting up his practice in 2000, he has treated patients with a wide range of urological diseases and specializes in oncological care. In addition to his practice, Franz is also a vaccinator at the Buchholz vaccination center. Managing Director Rüdiger Ludwig Rüdiger Ludwig is a lawyer specializing in commercial and corporate law and a partner at MÖHRLE HAPP LUTHER. His expertise includes corporate law, acquisitions (M&A) and corporate succession. Mr. Ludwig is a long-standing member of the board of directors or board of trustees of various foundations and advises founders and foundations. A lawyer since 1993, he was a founding partner of HAPP LUTHER and has been a partner at MÖHRLE HAPP LUTHER since 2010.